13D Filing: James E. Flynn and Proteon Therapeutics Inc (PRTO)

Page 13 of 17

(4) Deerfield Partners

Number of shares: 197,424

Percentage of shares: 1.12%*

(5) Deerfield Special Situations
Fund

Number of shares: 149,676

Percentage of shares: 0.85%*

(6) Deerfield International Master
Fund

Number of
Shares: 0

Percentage
of Shares: 0.00%

(7) Deerfield Private Design
Fund III

Number of
Shares: 877,799

Percentage
of Shares: 4.98%*

(8) Deerfield Private Design
Fund IV

Number of
Shares: 16,082,018

Percentage
of Shares: 9.985%*

(9) Deerfield Mgmt IV

Number of
Shares: 16,082,018

Percentage
of Shares: 9.985%*

(10) Flynn

Number of shares: 17,306,917

Percentage of shares: 9.985%*

*Percentage beneficial ownership reported
herein reflects 17,619,418 shares of Common Stock outstanding as of October 31, 2017, as reported in the Company’s Quarterly
Report on Form 10-Q for the quarterly period ended September 30, 2017.

(b)

(1) Deerfield Management

Sole power to vote or direct the
vote: 0

Shared power to vote or direct
the vote: 17,306,917

Sole power to dispose or to direct
the disposition: 0

Shared power to dispose or direct
the disposition: 17,306,917